Duration of dual anti-platelet therapy – State of the art after the DAPT and PEGASUS-TIMI 54 trials
| Autor: | Charles Pirlet, Olivier Gach, Victor Legrand, Luc Pierard, Astrid Nyssen |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
030204 cardiovascular system & hematology Coronary Restenosis 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Thrombolytic Therapy 030212 general & internal medicine Stent thrombosis Randomized Controlled Trials as Topic business.industry General Medicine Anti platelet Coronary heart disease Prosthesis Failure Surgery Treatment Outcome Cardiology Drug Therapy Combination Stents Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors TIMI |
| Zdroj: | Acta Cardiologica. 72:256-264 |
| ISSN: | 0373-7934 0001-5385 |
| Popis: | Dual anti-platelet therapy is prescribed in the setting of coronary heart disease for the prevention of stent thrombosis and acute thrombotic events. The optimal duration of dual anti-platelet therapy is still under debate as numerous trials have shown non-inferiority of a strategy of early cessation of one of the agents as compared to the standard practice whereas two larger trials have demonstrated benefit of prolonging dual anti-platelet therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|